/ /

CLINICAL

New treatments on the horizonEmerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.
Laser treatments found safe, effectiveA new study finds that use of dual laser therapy alone in skin types V and VI achieves excellent results with an exceptional side-effect profile.
Office-based alternative to in-home oral and topical regimenApplication of a topical photoparticle immediately before non-ablative 810 nm diode laser treatment for acne resulted in a statistically significant reduction from baseline in inflammatory acne counts on the back, according to a small feasibility study.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Study finds significant inpatient burden for AD patientsA recent study looked at the inpatient burden on patients with atopic dermatitis (AD) in the United States and found a significant financial burden due to the high hospitalization rates.
Hormonal therapies effective for acneHormonal therapies are an effective strategy to improve acne in women but some of these treatments, including birth control pills, are not commonly prescribed.
Isotretinoin still the best drug for acne
Isotretinoin still the best drug for acneAs part of its updated guidelines for the treatment of acne published early last year, the American Academy of Dermatology included new recommendations for the use of oral isotretinoin.
Impact of childhood atopic dermatitisInstructional handouts help caregivers stick to complicated treatment plans for pediatric AD patients. Historically effective AD treatments are being augmented with new phosphodiesterase inhibitors and biologics. Gentler approaches such as massage, light therapy, and melatonin may also be of value for children with AD.
Atopic dermatitis pipelineDrugs to treat atopic dermatitis are at the top of the FDA’s dermatology list. Biologics and PDE4 inhibitors show promise in the treatment of AD. Approval is still needed for the use of biologics to treat AD in pediatric patients.
A new class steps forwardPhosphodiesterase (PDE) inhibitors including apremilast and crisaborole ointment may provide safer alternatives than traditional steroid-sparing agents for psoriasis and atopic dermatitis. Side effects of apremilast may include GI symptoms, weight loss and depression, and taking apremilast with anti-seizure drugs or rifampin lowers apremilast blood levels, Apremilast is being studied in inflammatory bowel disease, Behcet's disease and pediatric psoriasis, and may have a place in the treatment of hidradenitis suppurativa (HS).

Poll

View Results